touchNEUROLOGY had the great pleasure of speaking with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease.
The abstract entitled ‘Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer’s Disease’ was presented at The 15th International Conference for Alzheimer’s & Parkinson’s Diseases (Virtual), March 8-14, 2021.
- Why is lenalidomide considered a potentially promising drug in the treatment of mild cognitive impairment in Alzheimer’s disease? (0:15)
- What is already known about the benefits of lenalidomide and thalidomide in AD? (2:23)
- What are the aims and design of the MCLENA study? (3:05)
- What are the clinical endpoints in the MCLENA study? (4:35)
- What data has been accrued to date? (5:07)
- What future developments do you have planned? (5:35)
Disclosures: Marwan Sabbagh has ownership interest (stock or stock options) in Brain Health Inc, NeuroReserve, NeuroTau, Optimal Cognitive Health Company, uMethod Health, Versanum, Athira; has been a consultant for Alzheon, Neurotrope, Biogen, Cortexyme, Danone, Regeneron, Roche-Genentech, Stage 2 Innovations, Acadia; and has royalties with HarperCollins. Marwan Sabbagh is also part of the speakers bureau for Health and Wellness Partners and Joyce Knapp Communications.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AD/PD Virtual 2021.
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Kristen George, AAIC 2022: Experiences of discrimination on cognitive function and ageing among the oldest old: The LifeAfter90 (LA90) Study
The LifeAfter90 (LA90) Study aims to understand what cognitive ageing and dementia look like among individuals aged 90 and above. In this interview, Dr Kristen George (University of California Davis School of Medicine, University of California, Davis, CA, USA) discussed what the study found in terms of the effect of discrimination on the cognitive function of this […]
Claire Sexton: Highlights of AAIC 2022
The Alzheimer’s Association International Conference (AAIC) is the largest and most influential meeting dedicated to advancing Alzheimer’s and dementia research. Each year, it gathers researchers to share discoveries that’ll lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer’s disease. Dr Claire Sexton is the senior director of Scientific Programs […]
Dr Jennifer Bute: Living with dementia – the importance of laughter and hope
Dr Jennifer Bute is a retired GP living with dementia. She shares her experiences of diagnosis and describes the strategies that are helpful for her. Jennifer also highlights the importance of laughter, engagement and hope. Touch Medical Media is sharing educational resources on World Brain Day (22 July 2022) to help achieve brain health for […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!